Evidence map›Paper›PMID 39199576›Full record

ArticleCancers2024

Development and Characterization of Syngeneic Orthotopic Transplant Models of Obesity-Responsive Triple-Negative Breast Cancer in C57BL/6J Mice.

Meredith S Carson, Patrick D Rädler, Jody Albright, Melissa VerHague, Erika T Rezeli, Daniel Roth, John E French, Charles M Perou, Stephen D Hursting, Michael F Coleman

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Meredith S CarsonDepartment of Nutrition, University of North Carolina, Chapel Hill, NC 27599, USA.
Patrick D RädlerDepartment of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA.
Jody AlbrightNutrition Research Institute, University of North Carolina, Kannapolis, NC 28081, USA.
Melissa VerHagueNutrition Research Institute, University of North Carolina, Kannapolis, NC 28081, USA.
Erika T RezeliDepartment of Nutrition, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0001-5468-0150
Daniel RothLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
John E FrenchDepartment of Nutrition, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-6092-2846
Charles M PerouDepartment of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA.
Stephen D HurstingDepartment of Nutrition, University of North Carolina, Chapel Hill, NC 27599, USA.
Michael F ColemanDepartment of Nutrition, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-6914-848X

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JAMES E BEAR · 1985 to 2026
$201.5M
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHARLES M PEROU · 1992 to 2026
$59.3M
UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ian Michael Carroll · 1999 to 2026
$31.6M
Therapeutic Targeting of Breast Cancer Tumor Initiating CellsR01CA148761 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, ROSEN, JEFFREY MARK · 2010 to 2025
$6.5M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
Obesity, Metabolism and Breast Cancer MetastasisR01CA232589 · NCI · PURDUE UNIVERSITY · PI HURSTING, STEPHEN D, TEEGARDEN, DOROTHY · 2019 to 2023
$2.6M
NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA058223NCI NIH HHS R01 CA148761NCI NIH HHS R01 CA232589NCI NIH HHS T32 CA057726NIDDK NIH HHS P30 DK056350NIH HHS CA16086NIH HHS P50-CA058223NIH HHS R01-CA148761NIH HHS R01-CA232589
6 · The paper itself

Abstract

Obesity is an established risk and progression factor for triple-negative breast cancer (TNBC), but preclinical studies to delineate the mechanisms underlying the obesity-TNBC link as well as strategies to break that link are constrained by the lack of tumor models syngeneic to obesity-prone mouse strains. C3(1)/SV40 T-antigen (C3-TAg) transgenic mice on an FVB genetic background develop tumors with molecular and pathologic features that closely resemble human TNBC, but FVB mice are resistant to diet-induced obesity (DIO). Herein, we sought to develop transplantable C3-TAg cell lines syngeneic to C57BL/6 mice, an inbred mouse strain that is sensitive to DIO. We backcrossed FVB-Tg(C3-1-TAg)cJeg/JegJ to C57BL/6 mice for ten generations, and spontaneous tumors from those mice were excised and used to generate four clonal cell lines (B6TAg1.02, B6TAg2.03, B6TAg2.10, and B6TAg2.51). We characterized the growth of the four cell lines in both lean and DIO C57BL/6J female mice and performed transcriptomic profiling. Each cell line was readily tumorigenic and had transcriptional profiles that clustered as claudin-low, yet markedly differed from each other in their rate of tumor progression and transcriptomic signatures for key metabolic, immune, and oncogenic signaling pathways. DIO accelerated tumor growth of orthotopically transplanted B6TAg1.02, B6TAg2.03, and B6TAg2.51 cells. Thus, the B6TAg cell lines described herein offer promising and diverse new models to augment the study of DIO-associated TNBC.

Indexed as

model developmentobesityorthotopic transplantationtriple-negative breast cancer

Identifiers

PMID39199576
PMCPMC11352691

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.